<u>XN 09/634,207</u> <u>PATENT</u>

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

pplicant: Dennis A. Carson et al. Examiner: Tamthom M. Truong

Serial No.: 09/634,207 Group Art Unit: 1624

Filed: August 09, 2000 Docket: 103.022US1
Title: INDOLE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER

INFORMATION DISCLOSURE STATEMENT

Mail Stop RCE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

NOV 2 2 2004

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 et. seq., the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicants respectfully request that this Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicants request that a copy of the 1449 form, initialed as being considered by the Examiner, be returned to the Applicants with the next official communication.

Pursuant to 37 C.F.R. §1.97(b), it is believed that no fee or statement is required with the Information Disclosure Statement. However, if an Office Action on the merits has been mailed, the Commissioner is hereby authorized to charge the required fees to Deposit Account No. 19-0743 in order to have this Information Disclosure Statement considered.

The Examiner is invited to contact the Applicants' Representative at the below-listed telephone number if there are any questions regarding this communication.

Respectfully submitted, DENNIS A. CARSON ET AL.

By their Representatives, SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A. P.O. Box 2938
Minneapolis, MN 55402

(612) 373-6968

Date November 19, 2004

William F. Prout

Reg. No. 33,995

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: MS RCD Commissioner for Patents 10. Box 1450, Alexandria, VA 22313-1450, on this 1927 day of November, 2004.

Signature

PTO/SB/08A(10-01)
Approved for use through 10/31/2022. OMB 651-0031
US Patient & Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1895, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE 09/634,207 **Application Number** STATEMENT BY APPLICANT E August 9, 2000 **Filing Date** (Use as many sheets as necessary) Carson, Dennis **First Named Inventor** NOV 2 2 2004 1624 **Group Art Unit** Truong, Tamthom **Examiner Name** Attorney Docket No: 103.022US1 Sheet 1 of 2

F	LICE De coment Number	Publication	ENT DOCUMENTS Name of Patentee or Applicant of cited Document Filing Date		
Examiner Initial *	USP Document Number	Date	Name of Patentee of Applicant of Cited Document	If Appropriate	
	US-2002/0042375A1	04/11/2002	Heimbrook, D. C., et al.	06/29/2001	
	US-2003/0004143A1	01/02/2003	Prior, C. P., et al.	04/18/2002	
	US-3,053,255	09/11/1962	Meyer, Friedrich	12/16/1958	
	US-3,710,795	01/16/1973	Higuchi, Takeru, et al.	09/29/1970	
	US-3,843,480	10/22/1974	Dreher, Donald F.	12/04/1967	
	US-3,939,178	02/17/1976	Demerson, Christopher A., et al.	09/15/1972	
	US-3,948,254	04/06/1976	Zaffaroni, Alejandro	08/28/1974	
	US-3,948,262	04/06/1976	Zaffaroni, Alejandro	03/10/1975	
	US-3,974,179	08/10/1976	Demerson, Christopher A., et al.	10/10/1974	
	US-3,993,073	11/23/1976	Zaffaroni, Alejandro	03/03/1975	
	US-4,310,509	01/12/1982	Berglund, Claire A., et al.	07/31/1979	
- 1	US-4,460,562	07/17/1984	Keith, Alec D., et al.	03/30/1983	
	US-4,466,953	08/21/1984	Keith, Alec D., et al.	09/30/1982	
	US-4,482,534	11/13/1984	Blank, Izhak	08/18/1983	
	US-4,485,097	11/27/1984	Bell, E.	05/25/1983	
	US-4,505,891	03/19/1985	Ito, Toshio		
	US-4,533,540	08/06/1985	Blank, Izhak	08/30/1984	
	US-4,542,012	08/17/1985	Dell, John D.	02/11/1983	
	US-4,542,013	09/17/1985	Keith, Alec D., et al.	08/16/1983	
	US-4,560,555	12/24/1985	Snider, Bruno	12/12/1983	
	US-4,585,877	04/29/1986	Demerson, Christopher A., et al.	05/06/1985	
	US-4,597,961	07/01/1986	Etscorn, Frank T.	01/23/1985	
	US-4,608,249	08/26/1986	Otsuka, Saburo	11/02/1982	
	US-4,686,213	08/11/1987	Ferdinandi, Eckhardt S., et al.	08/15/1986	
	US-4,748,252	05/31/1988	Ferdinandi, Eckhardt S., et al.	01/28/1987	
	US-4,806,356	02/21/1989	Shaw, Alec S.	04/03/1987	
	US-4,940,587	07/10/1990	Jenkins, Anthony W., et al.	06/03/1986	
	US-5,599,946	02/04/1997	Vincenzo, Giobbio , et al.	05/30/1995	
	US-5,776,967	07/07/1998	Kreft, Anthony F., et al.	07/07/1997	
	US-5,824,699	10/20/1998	Kreft, Anthony F., et al.	03/16/1998	
	US-5,968,974	10/19/1999	Kargman, Stacia, et al.	10/10/1997	
	US-5,981,592	11/09/1999	Wechter, W. J., et al.	04/09/1998	
	US-6,160,018	12/12/2000	Wechter, William J., et al.	03/10/1997	

EXAMINER DATE CONSIDERED

PTO/SB/08A(10-01)
Approved for use through 10/31/2002. OMB 651-0031
US Patent & Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO Complete if Known INFORMATION DISCLOSURE STATEMENT BY APPLICANT 09/634,207 **Application Number Filing Date** August 9, 2000 (Use as many sheets as necessary) Carson, Dennis **First Named Inventor** 1624 **Group Art Unit** NOV 2 2 2004 Truong, Tamthom **Examiner Name** Attorney Docket No: 103.022US1 Sheet 2 of 2

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	T ²				
	WO-0106990A2	02/01/2001	Carson, Dennis A.					
	WO-0212188A2	02/14/2002	Carson, Dennis A.					
	WO-9748391A3	12/24/1997	Xiaotao, Quian					
	WO-98/40078A1	09/17/1998	Rephaeli, A.					

	OTHE	R DOCUMENTS NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		HEATH, CLARK W., "Nonsteroidal Antiinflammatory Drugs and Human	
		Cancer", American Cancer Society, Voulme 74, Number 10, (November 15, 1994),2885-2886	
		MCCRACKEN, JOHN D., "Antiproliferative Effects of the Enantiomers of	
		Flurbiprofen", Journal of Clinical Pharmacology, (1996),540-545	
		PIAZZA, GARY A., "Apoptois Primarily Accounts for the Growth-inhibitory	
		Properties of Sulindac Metabolites and Involves a Mechanism That is	
		Independent of Cyclooxygebase Inhibition, Cell Cycles Arrest, and p53	
		Induction", Cancer Research, Volume 57, (June 15, 1997),2452-2459	ļ
		RILEY, et al., "New Drugs: a six month review", US Pharamacist, Vol. 16,	
		(September 1991),35-64	
		THUN, MICHAEL J., "Aspirin, NSAIDs, and digestive tract cancers", Cancer and Metastasis Reviews 13, Kluwer Academic Publishers., (1994),269-277	
		WECHTER, WILLIAM J., "R-Flurbiprofen (E-7869), a chemopreventive and treatment of cancer", Inflammopharmacology, Volume 8, No. 2, (2000),189-206	
		WECHTER, WILLIAM J., "R-Flurbiprofen Chemoprevention and Treatment of	
		Intestinal Adenomas in the APC min/+ Mouse Model: Implications for	
		Prophylaxis and Treartment of Colon Cancer", Cancer Research, Volume 57,	
		Number 19, (October 1, 1997),4316-4324	
		WECHTER, WILLIAM J., "Rac-Flurbiprofen Is More Ulcerogenic Than Its (S)-	
		Enantiomer", Chirality, Volume 5, Number 7, (1993),492-494	L

EXAMINER DATE CONSIDERED